Biologics safety testing market to be worth US$3.13bn by 2019, forecasts report

Growth of the pharma and biotech industries and an increasing number of new biologics products are driving growth

The global biologics safety testing market was valued at US$1.76bn in 2014 and is expected to grow at a CAGR of 12.23% to reach $3.13bn by 2019, according to a new market research report published by MarketsandMarkets.

The market is segmented based on product, test, application, and geography. By product, it is divided into instruments, kits and reagents, and services. Of these, the kits and reagents segment had the largest market share in 2014.

The application segments included in this report, Biologics Safety Testing Market by Application (Stem Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, Reagents), & Test (Bioburden, Endotoxin, Cell Line Authentication, Residual Contamination, Adventitious Agents) – Global Forecast to 2019, are blood and blood products, cellular and gene therapy products, stem cell products, tissues and tissue products, and vaccines and therapeutics. Of these, vaccines and therapeutics hold the highest share.

By test, the market is segmented into adventitious agents detection tests, bioburden tests, cell line authentication and characterization tests, endotoxin tests, residual host contaminant detection tests, sterility testing, and other tests (efficacy tests, toxicity tests, stability tests).

The demand for biologics safety testing products will also be further boosted by increasing government support

According to the report, the rapidly growing pharmaceutical and biotechnology industries and increasing number of new biologics products launched will be the two most important growth drivers for this market in the forecast period (2014-2019). The number of new products launched annually witnessed a strong upward trend in the decade between 2003 and 2013. The number of new products launched in 2013 was 56, compared with 29 in 2003. The biologics pipeline has increased by 155%, from 355 treatments in 2001 to 907 in 2012.

A strong pharmaceutical product pipeline will aid the growth of the pharmaceutical and biotechnology industry, which is an important end user of biologics safety testing products, the report says.

The demand for biologics safety testing products will also be further boosted by increasing government support for the pharmaceutical and biotechnology industries. In 2013, the European Research Council awarded $830m for life sciences research projects across Europe. A similar trend can be observed in Asia; for instance, from 2014, the Indian government plans to invest up to $5bn a year for the next five years to boost the biotechnology sector in the country and make it a $100bn industry by 2025. This increases the purchasing power of major research institutes, which in turn is driving the market for biologics safety testing products.

Major players in the market include Charles River Laboratories, Lonza Group, Sigma-Aldrich, SGS, WuXi PharmaTech, Avance Biosciences, BSL Bioservice, Cytovance Biologics, Merck & Co and Toxikon.

Companies